Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Closes on Public Offering, Raises $27.5M

NEW YORK (GenomeWeb News) – Rosetta Genomics said today it has closed its public offering, raising $27.5 million in gross proceeds.

The firm offered 5.5 million shares at $5 per share. Aegis Capital was the sole book-running manager for the offering. Rosetta granted the underwriter a 45-day option to purchase up to 825,000 additional shares to cover any overallotments.

The Israel-based developer of microRNA-based molecular diagnostics plans to use funds from the offering for general corporate purposes including repayment or refinancing of debt, capital investments, and R&D and product development efforts.

Rosetta filed a prospectus for the offering in June, at which time the company said it aimed to raise up to $35 million. Two weeks ago, it said it anticipated raising $27.7 million from an offering of 3 million shares, assuming a public offering price of $10.15 per share.

In afternoon trading on the Nasdaq, shares of Rosetta were up almost 4 percent at $4.40.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.